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Antifibrotic and molecular aspects of
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protocol for a randomized controlled trial
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Troels Havelund1 and Aleksander Krag1
Abstract
Background: Alcoholic liver disease is the leading cause of cirrhosis worldwide. Due to an increase in alcohol overuse,
alcoholic liver disease has become an increased burden on health care systems. Abstinence from alcohol remains the
cornerstone of alcoholic liver disease treatment; however, this approach is hampered by frequent relapse and lack of
specific therapy for treating advanced cases of liver disease. In the present study, we hypothesized that gut microbiota
drive the development of liver fibrosis and that modulation of gut microbiota with the gut-selective, nonabsorbable
antibiotic rifaximin attenuates alcoholic liver fibrosis.
Methods/design: Our double-blind, placebo-controlled trial will include 136 participants with biopsy-verified alcoholic
fibrosis (Ishak liver fibrosis score of 1–4). Participants are randomized 1:1 to receive placebo or 550 mg of rifaximin twice
daily for 18 months. A liver biopsy will be performed at the end of the treatment period to evaluate the effect of drug
treatment on liver fibrosis. Stool, urine, and saliva specimens will be collected before treatment begins, at 1 month, and
at the end of the treatment period. Fecal samples are used for microbiome deep sequencing. Changes in microbiome
composition are compared before and after the trial medication period and linked to changes in liver fibrosis.
Discussion: This is the first clinical trial to evaluate the effect of gut microbiota on liver fibrosis in humans. If gut
microbiota are an important promoter of alcoholic liver disease, current results may open new therapeutic avenues and
revolutionize the current understanding of chronic liver diseases.
Trial registration: EudraCT, 2014–001856-51. Registered on 16 August 2014.
Keywords: Liver fibrosis, Alcoholic liver disease, Gut microbiota, Rifaximin
Background
Alcohol consumption is the leading cause of liver
cirrhosis in humans, and mortality from alcoholic liver
disease compared to other common chronic diseases is
on the rise [1, 2]. Unfortunately, research related to
alcoholic liver disease is relatively underfunded and
subject to limited interest from pharmaceutical companies;
therefore, no new therapeutic interventions have been
developed in the last few decades [3]. Furthermore, patients
with this disease are often stigmatized, present a relatively
high socioeconomic burden, and are a key societal
challenge. Excessive alcohol consumption stimulates extra-
cellular matrix production from hepatic stellate cells, which
accumulates as liver fibrosis and replaces normal liver
tissue. Although the liver is able to recover to some extent,
sustained misuse of alcohol over several years can lead to
progressive accumulation of liver fibrosis and eventually
cirrhosis.
Due to its anatomical position, the liver is the first
organ to encounter bacteria and bacterial products from
the gut via portal venous blood. During alcoholic liver
disease, intestinal microbiota change qualitatively and
quantitatively in favor of a community with increased
invasive potential, and the gut barrier is compromised [4].
As a consequence, an increased load of bacterial products
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are transported to the liver, where they activate Toll-like
receptors, leading to proinflammatory gene expression
and fibrogenesis [5]. This cross-talk between intestinal
microbiota and the liver constitutes a gut-liver axis, which
has been increasingly recognized as a key mechanism in
the progression of alcoholic liver disease and pathogenesis
of liver-related complications [6, 7].
Study rationale
Modulation of gut microbiota using broad-spectrum
antibiotics is currently being used in clinical hepatology
to protect against complications associated with advanced
liver diseases, such as bacterial translocation, spontaneous
bacterial peritonitis, and recurrent episodes of hepatic
encephalopathy [7]. Rifaximin, a nonabsorbable derivative
of rifampicin, is currently being used to help treat
traveler’s diarrhea and prevent recurrent episodes of
hepatic encephalopathy in advanced liver disease [8].
Rifaximin exerts a broad-spectrum bactericidal effect
against gastrointestinal bacteria by binding to the β-
subunit of bacterial DNA-dependent RNA polymerase [9].
Previous studies have shown that rifaximin has a modest
impact on the composition of gut microbiota. However,
these studies were done in patients with end-stage liver
disease using a 16S ribosomal RNA gene sequencing with
limited microbiota sequencing depth [10, 11]. To date,
there have been no studies evaluating the possible antifi-
brotic effect of modulating human gut microbiota with
antibiotics. However, an increasing body of evidence from
animal studies, including models of alcoholic liver disease,
supports this notion [12, 13]. Due to its ability to selectively
target gut microbiota with minimal systemic uptake [14]
and its documented efficacy against complications related
to advanced liver disease [8], as well as liver fibrosis in a
preclinical model [13], we chose to use rifaximin to
modulate gut microbiota in the present clinical trial.
Study aim and hypothesis
We hypothesize that human gut microbiota and their
metabolites are major promoters of fibrosis in alcoholic
liver disease. Therefore, modulation of gut microbiota by
rifaximin can attenuate or halt disease progression by
decreasing the amount of profibrotic signals from gut
microbiota reaching the liver.
Methods/design
The present biopsy-controlled, double-blind study will
include a total of 136 patients randomized 1:1 to receive
a 550-mg tablet of rifaximin or placebo twice daily for
18 months. Randomization is being performed in blocks
of four, with stratification according to the Metavir
fibrosis score from initial liver biopsies and whether or
not participants abstained from alcohol for 6 months
prior to study onset. Participants are each assigned a
consecutively numbered three-digit identification number
in the trial. Each identification number is by chance
allocated to either placebo or rifaximin. The randomization
list is generated electronically by a central computer stored
at the pharmacy at Odense University Hospital (Odense,
Denmark); only authorized pharmacy personnel know the
randomization code. Sponsors, investigators, nurses, labora-
tory assistants, and/or personnel involved in trial partici-
pant care have no knowledge of the randomization. Sealed,
opaque envelopes with randomization keys for each partici-
pant are being kept at Odense University Hospital. Spon-
sors and investigators have access to the coded envelopes at
all times in case unblinding is necessary. Placebo tablets will
be similar in size, shape, and weight to the rifaximin tablet
to secure concealment. Pre- and post-treatment biopsies
are assessed together in a blinded manner by one expert
pathologist. Fecal samples are collected at home and frozen
immediately in a home freezer. They are transported to the
clinic in ice where they are stored at –80 °C. Samples are
processed for shotgun metagenomics sequencing of the gut
microbiota using the recommended procedures by the
International Human Microbiome Standards Consortium
[15]. Saliva samples are collected at the clinic in two tubes.
One tube is frozen to –80 °C immediately. The other is
stored at +5 °C for 3 h before freezing to –80 °C. Microbial
DNA extraction is performed with a Macherey-Nagel
NucleoSpin Kit, and 16S ribosomal RNA gene sequencing
of the oral microbiota is performed by amplifying the V4
hypervariable region using standard procedures [16]. Urine
samples are collected to detect the presence or absence of
ethyl glucuronide, a marker of alcohol consumption. For
further information, see the populated Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
checklist in Additional file 1.
Primary outcome measure
The primary outcome measure is the proportion of
patients with an improvement in their liver biopsy Ishak
(fibrosis) score greater than or equal to 1.
Secondary outcome measures
The secondary outcome measures are as follows:
 Markers of fibrosis: collagen proportionate area,
enhanced liver fibrosis score, Pro-C3, and hydroxy-
proline level
 Markers of matrix remodeling: tissue inhibitor of
metalloproteinase 1, matrix metallopeptidase 2, and
profibrotic cytokines (transforming growth factor
β1, platelet-derived growth factor β, and connective
tissue growth factor)
 Proinflammatory cytokines: tumor necrosis factor α,
monocyte chemoattractant protein 1, and cluster of
differentiation 163
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 Liver stiffness assessed by transient and shear wave
elastography
 Changes in the composition of the gut microbiota
assessed by shotgun metagenomics sequencing
 Quality of life assessed by the Short Form (36) Health
Survey and Chronic Liver Disease Questionnaire
 Nutritional status assessed by weight and hand
grip strength
Recruitment and enrollment of participants
Participants are being recruited from an ongoing obser-
vational study (Liver Disease in Alcohol Overusing Pa-
tients) at the department of Gastroenterology and
Hepatology, in which liver biopsies were taken from 400
patients with alcohol overuse (defined as the use of ≥ 24
g alcohol/day for women and ≥ 36 g alcohol/day for
men; approved by regional committees on health re-
search ethics for southern Denmark, project ID S-
20120071). Among these, a subset of 136 patients will be
enrolled in the current study if they comply with the in-
clusion and exclusion criteria outlined below.
Inclusion criteria
The inclusion criteria are as follows:
1. Women of child-bearing age and potential should
use safe contraception and provide a negative preg-
nancy test during the study period.
2. Patients with a liver fibrosis Ishak score of 1–4.
Exclusion criteria
The exclusion criteria are as follows:
1. Patients with a known allergy to rifaximin
2. Patients whom the investigator judges will not be or
are not compliant with the trial treatment protocol
3. Patients who received antibiotic treatment of any
kind 4 weeks prior to study onset
Study withdrawal
Patients will be withdrawn from the study for the follow-
ing reasons:
1. If blinding is repealed
2. If the patient undergoes treatment with another
antibiotic for more than 4 consecutive weeks or four
times during the study period
3. If the trial participant withdraws written consent
4. If the investigator judges that withdrawal is in the
participant’s best interest
Study dropouts
Trial participants will be classified as dropouts if they
meet either of the following criteria:
1. The trial participant ingests less than 75% of the
planned treatment.
2. The trial participant does not attend planned visits,
despite contact by telephone, letter, or mail.
Sample size calculation
According to a previous trial, alcoholic liver fibrosis was
calculated to regress in 27% of patients, remain un-
changed in 57%, and progress in 16% over a 2-year
period when patients with hepatitis C were excluded
[17]. Therefore, we estimated the natural history of re-
gression to be approximately 14% during an 18-month
period for our study population. The smallest relevant
difference is considered to be a 25% absolute increase in
the percentage of patients who regress by 1 point or
more in their histological score. If the risk of performing
type 1 and type 2 errors is set to 5% and 20%, respect-
ively, then 136 patients are needed when one performs a
power calculation using a two-sided test; this includes a
dropout rate of 20%. Both intent-to-treat and per proto-
col analyses will be performed.
Measurements and investigations
Measurements and investigations follow the study plan
outlined in Fig. 1.
During follow-up, the investigators or a study nurse
will keep a record of the medication and hand out new
trial medication to participants in the outpatient clinic
(Fig. 1); both used and unused trial medication is regis-
tered to keep track of the amount ingested by each par-
ticipant. In cases of uncertainty regarding the amount of
medicine ingested, the highest dose definitively known
will be registered. During the planned follow-up, adverse
events, alcohol consumption, and use of antibiotics will
be routinely registered in the case report form.
Drug information
Rifaximin is a semisynthetic analog of the antimicrobial
rifampicin that has an excellent safety profile and selective
impact on gut microbiota [10, 11, 18]. The tolerability of
long-term rifaximin use in patients with liver disease has
proven to be good in a previous study involving 299
patients. In that study, participants were randomized to
placebo (n = 159) or 550 mg of rifaximin (n = 140) twice a
day for 6 months in order to prevent recurrent hepatic
encephalopathy in patients with cirrhosis [8]. Their results
showed that rifaximin significantly reduced the risk of a
breakthrough episode of hepatic encephalopathy from
46% (placebo) to 22% (rifaximin). The majority of reported
side effects were of gastrointestinal origin, including nau-
sea and abdominal discomfort. The incidence of moderate
and serious adverse events was similar in patients receiv-
ing placebo or rifaximin [8].
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Risks and disadvantages for participants
Percutaneous liver biopsy is considered a safe investiga-
tion with few complications when used to diagnose non-
malignant hepatic disorders. However, most patients
experience some pain related to the puncture site.
Potential risks related to the procedure are intra-
abdominal bleeding, bile peritonitis, and perforation of
the gallbladder. The mortality rate is 1 in 10,000;
however, no deaths have been directly related to the
procedure when it is used to help diagnose the cause of
an abnormal liver function test. Major bleeding episodes
(the most frequent complication) appear in 2.2 out of
1000 biopsies in patients who are under further examin-
ation due to an abnormal liver function test [19]. To
minimize risk to the current trial participants, this
procedure will only be done by trial investigators or
medical staff with extensive experience. Furthermore,
there is no discomfort or risk related to B-mode
abdominal ultrasonography or ultrasound elastography.
Ethics
Currently there are no known effective drugs to treat
fibrotic liver disease, and the effects of rifaximin remain
unclear. Hence, no patient will be withheld medication
with proved efficacy by participating in this trial. All
patients should continue their regularly prescribed medi-
cations during the trial. Patients receiving placebo are
unlikely to experience any improvements in their disease
or symptoms due to the treatment per se. However, it is
necessary to treat half of the patients with placebo in
order to ascribe observed effects to rifaximin with
certainty. All patients are at risk for disease progression
and will benefit from close follow-up and early detection
of advanced liver disease by undergoing a liver biopsy.
During the trial, participants will be encouraged to
reduce their alcohol consumption. As suggested by a
previous study, many patients who overuse alcohol
included in clinical trials on alcoholic liver disease stop
drinking or reduce their alcohol consumption, causing
spontaneous improvement of their liver disease symp-
toms [20]. Overall, we believe the benefits of partici-
pating in this trial outnumber the risks, and we also
believe it to be ethically safe. Informed consent is
obtained from all participants.
Discussion
The present clinical trial is an investigator-initiated,
randomized, double-blind, placebo-controlled investigation
into the effect of rifaximin on human liver fibrosis. This
proof-of-concept trial is aimed at elucidating the role of
Fig. 1 Measurements and investigations. Legend section: SF-36 Short Form (36) Health Survey, CLDQ Chronic Liver Disease Questionnaire, AE adverse
event, *by transient and shear wave elastography, **by weight and hand grip strength
Madsen et al. Trials  (2018) 19:143 Page 4 of 5
profibrotic cross-talk between gut bacteria and the liver. If
gut bacteria are significant contributors to liver fibrosis,
modulation of gut flora could be a novel way to improve
outcomes in liver disease.
Trial status
The trial started enrolling participants March 2015. By
August 2017, 66 participants were enrolled and 25 had
completed the study. The last patient (n = 136 patients)
will be enrolled in December 2018. The estimated end of
follow-up and trial shutdown is June 2020.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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